CASI CASI Pharmaceuticals Inc.

4.25
-0.02  -0%
Previous Close 4.27
Open 4.25
Price To Book 3.51
Market Cap 397746939
Shares 93,587,515
Volume 339,147
Short Ratio
Av. Daily Volume 389,758

SEC filingsSee all SEC filings

  1. 8-K - Current report 181221024
  2. EFFECT - Notice of Effectiveness 181209766
  3. 8-K - Current report 181196193
  4. S-3 - Registration statement under Securities Act of 1933 181184634
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181180988

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 completed. Will not further development.
ENMD-2076
Cancer - Advanced/Metastatic Soft Tissue Sarcoma
Phase 2 initiated July 2012. Noted April 14, 2017 that further patient enrollment has been stopped.
ENMD-2076
Cancer - triple-negative breast cancer
Phase 2 initiated October 2015.
ENMD-2076
Cancer - fibrolamellar carcinoma (FLC)

Latest News

  1. The 4 Healthcare Stocks To Watch On Monday
  2. CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (Trademark: EVOMELA®)
  3. Chinese biotech stocks hit by a double whammy, which means it’s time to buy
  4. Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum — New Horizons, Emerging Trends, and Upcoming Developments
  5. CASI Pharmaceuticals To Build GMP Manufacturing Site In Wuxi, China
  6. CASI Pharmaceuticals Announces Third Quarter and First Nine Months 2018 Financial and Business Results
  7. Today’s Research Reports on Stocks to Watch: CASI Pharmaceuticals and Therapix Biosciences
  8. Why CASI Pharmaceuticals Inc. Is Rocketing Higher Today
  9. 3 Healthcare Stocks Trending Higher On News
  10. CASI Pharmaceuticals Acquires HBV ANDA from Laurus Labs Limited
  11. Detailed Research: Economic Perspectives on Beacon Roofing Supply, Rowan Companies, CASI Pharmaceuticals, LivePerson, Impinj, and Tredegar — What Drives Growth in Today's Competitive Landscape
  12. CASI Pharmaceuticals Announces Appointment Of President To Its China Operations To Lead Commercialization
  13. CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer
  14. CASI Pharmaceuticals Announces $48.5 Million Private Placement
  15. CASI Pharmaceuticals Announces Second Quarter And First Half 2018 Financial And Business Results
  16. Benzinga's Daily Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index
  17. CASI Pharmaceuticals Added To Russell 2000®, 3000® And Microcap® Indexes
  18. Here's Why CASI Pharmaceuticals Rose as Much as 31.6% Today

SEC Filings

  1. 8-K - Current report 181221024
  2. EFFECT - Notice of Effectiveness 181209766
  3. 8-K - Current report 181196193
  4. S-3 - Registration statement under Securities Act of 1933 181184634
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181180988
  6. 8-K - Current report 181180615
  7. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181180140
  8. 8-K/A [Amend] - Current report 181136968
  9. 8-K - Current report 181136906
  10. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181118690